| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Dapoxetine-d7 hydrochloride targets the serotonin transporter (SERT), the same target as unlabeled dapoxetine. As a deuterium-labeled compound, it exhibits the same pharmacological properties as dapoxetine hydrochloride but is distinguished by its mass for analytical purposes.
|
|---|---|
| ln Vitro |
In vitro, Dapoxetine-d7 hydrochloride behaves identically to unlabeled dapoxetine hydrochloride. It is a short-acting SSRI that inhibits serotonin reuptake. Its primary in vitro use is as an internal standard for the quantification of dapoxetine in biological samples.
|
| ln Vivo |
In vivo, Dapoxetine-d7 hydrochloride behaves identically to unlabeled dapoxetine hydrochloride. It is a short-acting SSRI used for the treatment of premature ejaculation. The deuterium label allows for pharmacokinetic studies and precise quantification of the drug and its metabolites.
|
| Enzyme Assay |
Non-cellular assays for Dapoxetine-d7 hydrochloride typically involve its use as an internal standard in analytical chemistry. It is spiked into samples, and the ratio of labeled to unlabeled dapoxetine is measured by GC- or LC-MS to quantify the amount of dapoxetine present.
|
| Cell Assay |
In vitro cellular assays for Dapoxetine-d7 hydrochloride are not typically performed, as it is primarily used as an analytical standard. Its pharmacological activity is identical to unlabeled dapoxetine.
|
| Animal Protocol |
In vivo animal experiments for Dapoxetine-d7 hydrochloride would involve administering the compound to animals to study the pharmacokinetics of dapoxetine. The deuterium label allows for precise tracking of the drug and its metabolites in biological samples.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties: Dapoxetine-d7 hydrochloride behaves identically to unlabeled dapoxetine hydrochloride. Dapoxetine is a short-acting SSRI with rapid absorption and elimination. The deuterium label does not significantly affect its pharmacokinetic profile.
|
| Toxicity/Toxicokinetics |
Toxicological profile: Dapoxetine-d7 hydrochloride is a stable isotope-labeled compound with the same toxicological properties as unlabeled dapoxetine hydrochloride. It is intended for research use only and not for human consumption.
|
| References | |
| Additional Infomation |
Dapoxetine-d7 hydrochloride has a molecular weight of 348.92 and a molecular formula of C21H24ClNO. Its CAS number is 2699607-47-9. It is intended for use as an internal standard for the quantification of dapoxetine by GC- or LC-MS. It is supplied for research purposes only.
|
| Molecular Formula |
C21H17D7CLNO
|
|---|---|
| Molecular Weight |
348.92
|
| Related CAS # |
Dapoxetine hydrochloride;129938-20-1;Dapoxetine;119356-77-3
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~250 mg/mL (~716.50 mM)
H2O :~50 mg/mL (~143.30 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.96 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.96 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.96 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8660 mL | 14.3299 mL | 28.6599 mL | |
| 5 mM | 0.5732 mL | 2.8660 mL | 5.7320 mL | |
| 10 mM | 0.2866 mL | 1.4330 mL | 2.8660 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
